Press Releases

About Us
Pipeline
Clinical Trials
Our Approach
Investors
Contact Us

Search Mobile

Overview

Normal

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012

September 30, 2014

ADC Therapeutics Expands Team

Download PDF format download (opens in new window)

May 29, 2014

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

Download PDF format download (opens in new window)

Quick Links

SEC Filings
Investor FAQs
Information Request Form

IR Contact

Amanda Hamilton

+1 917-288-7023
Send Email

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At ADC Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to ADC Therapeutics to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote



Enter the code shown above.

Unsubscribe

Email Alert Sign Up Confirmation

REQUEST A MEETING WITH MANAGEMENT